NEW YORK (GenomeWeb) – Roche today announced the US Food and Drug Administration has approved the company's Cobas cytomegalovirus test for use on the fully automated Cobas 6800 and 8800 systems.

The real-time PCR-based Cobas CMV test is for assessing how transplant patients on therapy respond to treatment. It offers an expanded linear rage from 34.5 IU/mL to 1E+07 IU/mL with robust coverage across genotypes, Roche said, adding that the test minimizes variability and complexity testing, reducing workload and risk for laboratories offering laboratory-developed tests.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.